SCHEMBL3712252

SCHEMBL3712252

O=C(C1=C(O)C(=O)N(CCc2ccccc2)C1c1ccc(Br)cc1)C1CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.65
MDM2 Q00987 1/20 0.65
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
USP7 Q93009 1/20 0.54
FPR1 P21462 3/20 0.48
HTT P42858 2/20 0.48
HIF1A Q16665 1/20 0.48
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 4/20 0.47
RXFP1 Q9HBX9 3/20 0.47
PPARG P37231 1/20 0.47
NCOA2 Q15596 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
ALOX15 P16050 5/20 0.47
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
GAA P10253 3/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707736 0.87 ALOX15 (0.59) TP53MDM2MEN1KMT2AUSP7
SCHEMBL3705340 0.86 MEN1 (0.78) TP53MDM2MEN1KMT2AUSP7
SCHEMBL3704381 0.81 MEN1 (0.70) TP53MDM2MEN1KMT2AUSP7
SCHEMBL3714403 0.80 USP7 (0.69) TP53MDM2MEN1KMT2AUSP7
SCHEMBL3705385 0.80 USP7 (0.79) TP53MDM2MEN1KMT2AUSP7
SCHEMBL3709204 0.80 MEN1 (0.74) TP53MDM2MEN1KMT2AUSP7
SCHEMBL3715641 0.79 MEN1 (0.73) TP53MDM2MEN1KMT2AUSP7
SCHEMBL3714413 0.76 USP7 (0.73) TP53MDM2MEN1KMT2AUSP7
SCHEMBL3705035 0.76 KDM4E (0.66) TP53MDM2MEN1KMT2AUSP7
SCHEMBL3707576 0.75 KDM4E (0.64) TP53MDM2MEN1KMT2AUSP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed